Market revenue in 2021 | USD 1.4 million |
Market revenue in 2032 | USD 8.6 million |
Growth rate | 18% (CAGR from 2021 to 2032) |
Largest segment | Chronic immunomodulators |
Fastest growing segment | Monoclonal Antibodies |
Historical data | 2018 - 2020 |
Base year | 2021 |
Forecast period | 2022 - 2032 |
Quantitative units | Revenue in USD million |
Market segmentation | Cholinesterase Inhibitors, Chronic Immunomodulators, Monoclonal Antibodies, Rapid Immunotherapies, Thymectomy |
Key market players worldwide | AstraZeneca PLC, Grifols SA Ordinary Shares - Class A, Avadel Pharmaceuticals PLC, Novartis AG ADR, Pfizer Inc, AbbVie Inc, Roche Holding AG, GlaxoSmithKline, Bausch Health Companies Inc, Takeda Pharmaceutical Co Ltd |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to myasthenia gravis treatment market will help companies and investors design strategic landscapes.
Chronic immunomodulators was the largest segment with a revenue share of 28.57% in 2021. Horizon Databook has segmented the Saudi Arabia myasthenia gravis treatment market based on cholinesterase inhibitors, chronic immunomodulators, monoclonal antibodies, rapid immunotherapies, thymectomy covering the revenue growth of each sub-segment from 2018 to 2032.
According to a study published by NCBI, in Saudi Arabia, MG affects younger individuals more as compared to other racial groups and thymectomy confers substantial benefits toward achievement of remission.
Furthermore, according to a study published by BMC Neurology, in June 2020, in Saudi Arabia, the rate of depression in individuals suffering from MG is higher than that in primary care clinic patients and comparable to that reported in patients with MG in other countries.
The growth of Saudi Arabia myasthenia gravis treatment market can mainly be attributed to increasing government initiatives and investments to provide better diagnosis & treatment options for rare diseases in the country.
Horizon Databook provides a detailed overview of country-level data and insights on the Saudi Arabia myasthenia gravis treatment market , including forecasts for subscribers. This country databook contains high-level insights into Saudi Arabia myasthenia gravis treatment market from 2018 to 2032, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account